Medical Pharmacology Chapter 29 Diabetes Management Practice Questions

Liraglutide (Victoza): is classified as belonging to the GLP-1 receptor agonist class of type II diabetes medications.
1. True
2. False
Liraglutide (Victoza):
1. Soluble fatty acid acylated GLP-1 analog
2. Relatively long-acting GLP-1 analog
3. Both
4. Neither
Liraglutide extended half-life:
1. About one hour
2. About 7 hours
3. About 13 hours
4. About 24 hours
Liraglutide (Victoza) metabolism:
1. Mainly through cytochrome P450 oxidation reactions.
2. Mainly metabolized by dipeptidyl peptidase IV (DPP-IV) as well as endogenous endopeptidases.
3. Both
4. Either
Pharmacokinetics of liraglutide: pharmacokinetic behavior in type II diabetes mellitus patients 10-17 years of age comparable to that of an adult.
1. True
2. False
Liraglutide:
1. Promotes glucose-dependent insulin release
2. Decreases inappropriate glucagon release
3. Both
4. Neither
Extended duration of liraglutide (i.e. increase half-life):
1. Increased plasma protein binding, particularly albumin, mainly accounts for extended half-life.
2. The fatty acid side chain associated with this molecule appears to reduce inactivating cleavage by DPP-4 (dipeptidyl peptidase-IV).
3. Both
Liraglutide and the cardiovascular system of patients both with type II diabetes and documented cardiovascular disease:
1. Decreases risk of death due to cardiovascular disease
2. Decreases the risk of nonfatal myocardial infarction
3. Decreases risk of nonfatal stroke
4. A & B
5. B & C
6. A & C
7. A, B & C
Liraglutide indication: treatment as an adjunct agent in those patients whose glycemic control is inadequately managed with oral agents
1. True
2. False
Liraglutide route/routes of administration:
1. Subcutaneous in upper arm, abdomen or thigh
2. Intravenous route of administration
3. Both
4. Neither
Positive effects associated with cardiovascular risk in patients with type II diabetes and documented cardiovascular disease associated with:
1. Exenatide
2. Lixisenatide
3. Both
4. Neither
Effect/effects associated with liraglutide (Victoza):
1. Reduction in HbA1c levels
2. Weight loss
3. Reduced systolic blood pressure
4. Decreased incidence of significant hypoglycemia
5. A & B
6. B & C
7. All of the above (A, B, C & D)
Liraglutide (Victoza) is contraindicated for chronic weight management in pregnant women.
1. True
2. False
Liraglutide (Victoza) is contraindicated in those patients exhibiting a personal or family history of medullary thyroid cancer as well as in patients with multiple endocrine neoplasia syndrome type 2.
1. True
2. False